
TWST Stock Forecast & Price Target
TWST Analyst Ratings
Bulls say
Twist Bioscience is well positioned because its silicon-based DNA synthesis platform lowers cost and increases throughput, addressing a core bottleneck in synthetic biology while supporting both NGS and DNA synthesis demand. The company is seeing strong AI-driven orders that are expected to reach triple-digits % in FY26, with at least ~$50M versus ~$25M in FY25, reinforcing a durable multi-year tailwind rather than a short-lived spike. Beyond AI, NGS remains a major growth engine expected to stay above 20% growth by FQ4 and contribute to FY26 revenue guidance of $446M, with expanding gross margins and a path to Adj. EBITDA breakeven by FQ4 adding further earnings leverage.
Bears say
Twist Bioscience is viewed negatively because it trades at a significant premium in a highly competitive life sciences tools market where incumbents like Danaher, Agilent, and Roche can bundle offerings and pressure pricing, limiting the company’s ability to sustain outsized margins. Its growth thesis also depends on AI-driven demand and NGS momentum, but the August 2026 stock surge was only a benchmark study, not a strategic partnership, and there is no clear evidence that NVO needs to use TWST alongside Claude Science. With profitability still dependent on gross margin improvement and disciplined expense control, any slower-than-expected adoption, weaker demand, or added investment could delay breakeven and weigh on valuation.
This aggregate rating is based on analysts' research of Twist Bioscience Corp and is not a guaranteed prediction by Public.com or investment advice.
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Twist Bioscience Corp (TWST) Forecast
TWST Analyst Forecast & Price Prediction
Start investing in TWST
Order type
Buy in
Order amount
Est. shares
0 shares